Selected research
Industry Research
Fenofibrate API Industry Research Report 2026
Market perspective
The global Fenofibrate API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fenofibrate API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fenofibrate API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fenofibrate API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fenofibrate API include Alembic Pharmaceuticals Limited, Clearsynth, CordenPharma, Enomark Pharma, IOL Chemicals, Lavybens pharma, Moehs Iberica S.L., MuseChem Chemicals and Niksan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fenofibrate API market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fenofibrate API Market by Company
Alembic Pharmaceuticals Limited
Clearsynth
CordenPharma
Enomark Pharma
IOL Chemicals
Lavybens pharma
Moehs Iberica S.L.
MuseChem Chemicals
Niksan Pharmaceutical
Omchemlabs
Sudarshan Pharma
Jiangsu Nhwa Pharmaceutical Co., Ltd
Zhejiang Excel Pharmaceutical Co.,Ltd.
Yongtai Tech
Chongqing Southwest Pharmaceutical
Fenofibrate API Segment by Type
Purity≥99%
Purity<99%
Fenofibrate API Segment by Application
Tablet
Capsule
Others
Fenofibrate API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fenofibrate API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fenofibrate API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fenofibrate API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fenofibrate API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fenofibrate API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fenofibrate API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity≥99%
- Purity<99%
Applications
- Tablet
- Capsule
- Others
Companies covered
- Alembic Pharmaceuticals Limited
- Clearsynth
- CordenPharma
- Enomark Pharma
- IOL Chemicals
- Lavybens pharma
- Moehs Iberica S.L.
- MuseChem Chemicals
- Niksan Pharmaceutical
- Omchemlabs
- Sudarshan Pharma
- Jiangsu Nhwa Pharmaceutical Co., Ltd
- Zhejiang Excel Pharmaceutical Co.,Ltd.
- Yongtai Tech
- Chongqing Southwest Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fenofibrate API Market Size (2021-2032)
- 2.2.2 Global Fenofibrate API Sales (2021-2032)
- 2.2.3 Global Fenofibrate API Market Average Price (2021-2032)
- 2.3 Fenofibrate API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity≥99%
- 2.3.3 Purity<99%
- 2.4 Fenofibrate API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tablet
- 2.4.3 Capsule
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fenofibrate API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fenofibrate API Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Fenofibrate API Revenue of Manufacturers (2021-2026)
- 3.4 Global Fenofibrate API Average Price by Manufacturers (2021-2026)
- 3.5 Global Fenofibrate API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fenofibrate API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fenofibrate API, Product Type & Application
- 3.8 Global Manufacturers of Fenofibrate API, Established Date
- 3.9 Global Fenofibrate API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alembic Pharmaceuticals Limited
- 4.1.1 Alembic Pharmaceuticals Limited Company Information
- 4.1.2 Alembic Pharmaceuticals Limited Business Overview
- 4.1.3 Alembic Pharmaceuticals Limited Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alembic Pharmaceuticals Limited Fenofibrate API Product Portfolio
- 4.1.5 Alembic Pharmaceuticals Limited Recent Developments
- 4.2 Clearsynth
- 4.2.1 Clearsynth Company Information
- 4.2.2 Clearsynth Business Overview
- 4.2.3 Clearsynth Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Clearsynth Fenofibrate API Product Portfolio
- 4.2.5 Clearsynth Recent Developments
- 4.3 CordenPharma
- 4.3.1 CordenPharma Company Information
- 4.3.2 CordenPharma Business Overview
- 4.3.3 CordenPharma Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CordenPharma Fenofibrate API Product Portfolio
- 4.3.5 CordenPharma Recent Developments
- 4.4 Enomark Pharma
- 4.4.1 Enomark Pharma Company Information
- 4.4.2 Enomark Pharma Business Overview
- 4.4.3 Enomark Pharma Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Enomark Pharma Fenofibrate API Product Portfolio
- 4.4.5 Enomark Pharma Recent Developments
- 4.5 IOL Chemicals
- 4.5.1 IOL Chemicals Company Information
- 4.5.2 IOL Chemicals Business Overview
- 4.5.3 IOL Chemicals Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 IOL Chemicals Fenofibrate API Product Portfolio
- 4.5.5 IOL Chemicals Recent Developments
- 4.6 Lavybens pharma
- 4.6.1 Lavybens pharma Company Information
- 4.6.2 Lavybens pharma Business Overview
- 4.6.3 Lavybens pharma Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lavybens pharma Fenofibrate API Product Portfolio
- 4.6.5 Lavybens pharma Recent Developments
- 4.7 Moehs Iberica S.L.
- 4.7.1 Moehs Iberica S.L. Company Information
- 4.7.2 Moehs Iberica S.L. Business Overview
- 4.7.3 Moehs Iberica S.L. Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Moehs Iberica S.L. Fenofibrate API Product Portfolio
- 4.7.5 Moehs Iberica S.L. Recent Developments
- 4.8 MuseChem Chemicals
- 4.8.1 MuseChem Chemicals Company Information
- 4.8.2 MuseChem Chemicals Business Overview
- 4.8.3 MuseChem Chemicals Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MuseChem Chemicals Fenofibrate API Product Portfolio
- 4.8.5 MuseChem Chemicals Recent Developments
- 4.9 Niksan Pharmaceutical
- 4.9.1 Niksan Pharmaceutical Company Information
- 4.9.2 Niksan Pharmaceutical Business Overview
- 4.9.3 Niksan Pharmaceutical Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Niksan Pharmaceutical Fenofibrate API Product Portfolio
- 4.9.5 Niksan Pharmaceutical Recent Developments
- 4.10 Omchemlabs
- 4.10.1 Omchemlabs Company Information
- 4.10.2 Omchemlabs Business Overview
- 4.10.3 Omchemlabs Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Omchemlabs Fenofibrate API Product Portfolio
- 4.10.5 Omchemlabs Recent Developments
- 4.11 Sudarshan Pharma
- 4.11.1 Sudarshan Pharma Company Information
- 4.11.2 Sudarshan Pharma Business Overview
- 4.11.3 Sudarshan Pharma Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sudarshan Pharma Fenofibrate API Product Portfolio
- 4.11.5 Sudarshan Pharma Recent Developments
- 4.12 Jiangsu Nhwa Pharmaceutical Co., Ltd
- 4.12.1 Jiangsu Nhwa Pharmaceutical Co., Ltd Company Information
- 4.12.2 Jiangsu Nhwa Pharmaceutical Co., Ltd Business Overview
- 4.12.3 Jiangsu Nhwa Pharmaceutical Co., Ltd Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Jiangsu Nhwa Pharmaceutical Co., Ltd Fenofibrate API Product Portfolio
- 4.12.5 Jiangsu Nhwa Pharmaceutical Co., Ltd Recent Developments
- 4.13 Zhejiang Excel Pharmaceutical Co.,Ltd.
- 4.13.1 Zhejiang Excel Pharmaceutical Co.,Ltd. Company Information
- 4.13.2 Zhejiang Excel Pharmaceutical Co.,Ltd. Business Overview
- 4.13.3 Zhejiang Excel Pharmaceutical Co.,Ltd. Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Zhejiang Excel Pharmaceutical Co.,Ltd. Fenofibrate API Product Portfolio
- 4.13.5 Zhejiang Excel Pharmaceutical Co.,Ltd. Recent Developments
- 4.14 Yongtai Tech
- 4.14.1 Yongtai Tech Company Information
- 4.14.2 Yongtai Tech Business Overview
- 4.14.3 Yongtai Tech Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Yongtai Tech Fenofibrate API Product Portfolio
- 4.14.5 Yongtai Tech Recent Developments
- 4.15 Chongqing Southwest Pharmaceutical
- 4.15.1 Chongqing Southwest Pharmaceutical Company Information
- 4.15.2 Chongqing Southwest Pharmaceutical Business Overview
- 4.15.3 Chongqing Southwest Pharmaceutical Fenofibrate API Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Chongqing Southwest Pharmaceutical Fenofibrate API Product Portfolio
- 4.15.5 Chongqing Southwest Pharmaceutical Recent Developments
5 Global Fenofibrate API Market Scenario by Region
- 5.1 Global Fenofibrate API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fenofibrate API Sales by Region: 2021-2032
- 5.2.1 Global Fenofibrate API Sales by Region: 2021-2026
- 5.2.2 Global Fenofibrate API Sales by Region: 2027-2032
- 5.3 Global Fenofibrate API Revenue by Region: 2021-2032
- 5.3.1 Global Fenofibrate API Revenue by Region: 2021-2026
- 5.3.2 Global Fenofibrate API Revenue by Region: 2027-2032
- 5.4 North America Fenofibrate API Market Facts & Figures by Country
- 5.4.1 North America Fenofibrate API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fenofibrate API Sales by Country (2021-2032)
- 5.4.3 North America Fenofibrate API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Fenofibrate API Market Facts & Figures by Country
- 5.5.1 Europe Fenofibrate API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fenofibrate API Sales by Country (2021-2032)
- 5.5.3 Europe Fenofibrate API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Fenofibrate API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fenofibrate API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fenofibrate API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fenofibrate API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fenofibrate API Market Facts & Figures by Country
- 5.7.1 South America Fenofibrate API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fenofibrate API Sales by Country (2021-2032)
- 5.7.3 South America Fenofibrate API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Fenofibrate API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fenofibrate API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fenofibrate API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fenofibrate API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Fenofibrate API Sales by Type (2021-2032)
- 6.1.1 Global Fenofibrate API Sales by Type (2021-2032) & (t)
- 6.1.2 Global Fenofibrate API Sales Market Share by Type (2021-2032)
- 6.2 Global Fenofibrate API Revenue by Type (2021-2032)
- 6.2.1 Global Fenofibrate API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fenofibrate API Revenue Market Share by Type (2021-2032)
- 6.3 Global Fenofibrate API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fenofibrate API Sales by Application (2021-2032)
- 7.1.1 Global Fenofibrate API Sales by Application (2021-2032) & (t)
- 7.1.2 Global Fenofibrate API Sales Market Share by Application (2021-2032)
- 7.2 Global Fenofibrate API Revenue by Application (2021-2032)
- 7.2.1 Global Fenofibrate API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fenofibrate API Revenue Market Share by Application (2021-2032)
- 7.3 Global Fenofibrate API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fenofibrate API Value Chain Analysis
- 8.1.1 Fenofibrate API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fenofibrate API Production Mode & Process
- 8.2 Fenofibrate API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fenofibrate API Distributors
- 8.2.3 Fenofibrate API Customers
9 Global Fenofibrate API Analyzing Market Dynamics
- 9.1 Fenofibrate API Industry Trends
- 9.2 Fenofibrate API Industry Drivers
- 9.3 Fenofibrate API Industry Opportunities and Challenges
- 9.4 Fenofibrate API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst